Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT05508932
Recruiting Observational

Atrial Fibrillation in Beta-Thalassemia

NCT05508932 · tracked via the Priya Life Science Italy tracker
Sponsor
University Hospital of Ferrara
Phase
Observational
Started
2022-09-01
Last updated
2026-02-24

Condition(s) studied

Atrial FibrillationThalassemia

Study summary

The study aims to evaluate the clinical, laboratory and instrumental differences that exist between beta-thalassemia patients with atrial fibrillation and those not affected by arrhythmia.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Transfusion-dependent Beta-thalassemia; 2. Follow-Up at the Cardiology Unit of the University Hospital of Ferrara; 3. Electrocardiogram performed; 4. Echocardiogram performed. Exclusion Criteria: 1. Age \<18 years; 2. State Of pregnancy; 3. Inability to give informed consent.

Primary outcome measure(s)

  • Atrial fibrillation — 10 years
    New onset of Atrial Fibrillation documented at ECG

Trial sites (1)

FacilityCityRegionStatus
Matteo Bertini Ferrara Italy Recruiting

More University Hospital of Ferrara trials in Italy

Effects of Physical Exercise and Cognitive Training on Quality of Life in Older Women Starting soon
Diagnostic Accuracy of 18F-FDG PET/CT in Muscle-invasive Bladder Cancer Recruiting
ConTempoRary Cardiac Stimulation in Clinical practicE: lEft, BivEntriculAr, Right, and conDuction System Pacing Recruiting
Unravelling The Optimisation And Consolidation Of Motor Skills In People With Multiple Sclerosis With Severe Gait Impairment: A Feasibility Study Recruiting
Observational Study Relating to the Long-term Follow-up of Patients with Severe Aortic Stenosis Evaluated for Percutaneous Aortic Valve Replacement (TAVI). Enrolling by invitation

Other trials for the same condition

The Fourth Left Atrial Appendage Occlusion Study Recruiting
ConTempoRary Cardiac Stimulation in Clinical practicE: lEft, BivEntriculAr, Right, and conDuction System Pacing Recruiting
A Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation Active, not recruiting
Wide-Antral Pulmonary Vein Isolation in Atrial Fibrillation Ablation with a Single-shot Technique (WIDER-PVI) Recruiting
Pericardiotomy in Cardiac Surgery Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05508932 on ClinicalTrials.gov ↗ ← All trials in Italy